Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7171 to 7185 of 8235 results

  1. Azacitidine for treating relapsed or refractory angioimmunoblastic T-cell lymphoma [ID3864]

    Discontinued Reference number: GID-TA10750

    Technology appraisal guidance
    Discontinued

  2. Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872]

    In development Reference number: GID-TA10758 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]

    Discontinued Reference number: GID-TA10763

    Technology appraisal guidance
    Discontinued

  4. Pevonedistat with azacitidine for untreated myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia [ID3877]

    Discontinued Reference number: GID-TA10767

    Technology appraisal guidance
    Discontinued

  5. Bintrafusp alfa for treating advanced biliary tract cancer after platinum-based chemotherapy [ID3874]

    Discontinued Reference number: GID-TA10768

    Technology appraisal guidance
    Discontinued

  6. Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]

    In development Reference number: GID-TA10780 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]

    In development Reference number: GID-TA10800 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Amcenestrant for treating ER-positive, HER2-negative advanced breast cancer after hormonal therapy [ID3919]

    Discontinued Reference number: GID-TA10803

    Technology appraisal guidance
    Discontinued

  9. Lasmiditan for treating acute migraine [ID3759]

    Discontinued Reference number: GID-TA10807

    Technology appraisal guidance
    Discontinued

  10. AT406 for neoadjuvant treatment of epithelial ovarian cancer [ID1428]

    Discontinued Reference number: GID-TA10809

    Technology appraisal guidance
    Discontinued

  11. Lenvatinib with pembrolizumab for untreated advanced or unresectable hepatocellular carcinoma [ID3930]

    Discontinued Reference number: GID-TA10811

    Technology appraisal guidance
    Discontinued

  12. Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]

    In development Reference number: GID-TA10822 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments [TSID11830] [ID6247]

    In development Reference number: GID-TA11251 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Durvalumab with concurrent chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906]

    Discontinued Reference number: GID-TA10783

    Technology appraisal guidance
    Discontinued

  15. Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes [ID3996]

    Discontinued Reference number: GID-TA10897

    Technology appraisal guidance
    Discontinued